This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic (MDT) Sees a Mixed Q1, New Products Bode Well
by Zacks Equity Research
Despite mixed results in Q1, Medtronic (MDT) displayed balanced growth with strength in three of its major business segments.
Abbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm
by Zacks Equity Research
Abbott Laboratories' (ABT) receipt of FDA approval for its Full MagLev HeartMate 3 LVAD strengthens one of its major business segments.
The Zacks Analyst Blog Highlights: Occidental Petroleum, HP, Anthem, Medtronic and Ulta Beauty
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Occidental Petroleum, HP, Anthem, Medtronic and Ulta Beauty
Company News For August 23, 2017
by Zacks Equity Research
Companies in the news are: VZ,LOW,CLX,CRM
Medtronic's (MDT) CE Mark in Heart Lead Strengthens CVG Arm
by Zacks Equity Research
Medtronic's (MDT) CVG arm continues to be the highest revenue grossing segment. Thus, the company's CE Mark receipt for Attain Stability Quad MRI SureScan Active-Fixation heart lead buoys optimism.
Medtronic (MDT) Beats Q1 Earnings, Misses Revenue Estimates
by Zacks Equity Research
Medtronic (MDT) rides high in Q1 on strength in three major business segments.
The Final Phase Of Q2 Earnings
by Zacks Equity Research
The Final Phase Of Q2 Earnings
Macy's Plucks eBay Exec, More Q2 Earnings: MDT, TOL, JASO
by Mark Vickery
While Macy's (M) streamlines operations, and as we wrap up Q2 earnings season, we still have a few notable companies worth hearing from.
Medtronic (MDT) Tops Q1 Earnings, Reiterates '18 Guidance
by Zacks Equity Research
Medtronic's (MDT) year-over-year top line performance was also impressive across all business groups except Diabetes Group which witnessed 1% decrease at CER.
Medtronic (MDT) Q1 Earnings: Stock Likely to Beat Again?
by Zacks Equity Research
Medtronic (MDT) well positioned to report strong earnings in Q1 banking on multiple developments and approvals.
Medtronic Announces RESOLUTE ONYX ONE-MONTH DAPT Study
by Zacks Equity Research
Medtronic (MDT) announces a clinical trial to evaluate one-month dual antiplatelet therapy in patients implanted with the Resolute Onyx Drug-Eluting Stent during PCI procedures.
Should You Sell Medtronic (MDT) Before Earnings?
by Zacks Equity Research
Medtronic (MDT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.
The Zacks Analyst Blog Highlights: Chevron, Wells Fargo & Company, Medtronic, Sony and EOG Resources
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chevron, Wells Fargo & Company, Medtronic, Sony and EOG Resources
Top Analyst Reports for Chevron, Wells Fargo & Medtronic
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), Wells Fargo & Company (WFC) and Medtronic plc (MDT).
Company News For August 1, 2017
by Zacks Equity Research
Companies in the news are: DVAX,SNI,MDT,CAH,DISC,LH
United Therapeutics (UTHR) Incurs Loss in Q2, Sales Top
by Zacks Equity Research
United Therapeutics Corporation (UTHR) incurred a loss in Q2. However, stronger sales across the PAH franchise pulled up the top line in the quarter.
Medtronic InterStim System Shows Five-Year Positive Results
by Zacks Equity Research
Medtronic plc (MDT) has announced that its InterStim system provides sustained long-term efficacy and improved quality of life for overactive bladder (OAB) patients at the end of five years.
Medtronic Enrolls First Patient Under STOP AF First Trial
by Zacks Equity Research
Medtronic (MDT) recently announced the first enrollment to its STOP AF First clinical trial.
FDA Approval Widens Medtronic's (MDT) TAVR Platform Reach
by Zacks Equity Research
Medtronic plc (MDT), a well established player in the medical technology, services and solutions space, recently announced FDA approval for the extended use of its self-expanding CoreValve Evolut transcatheter aortic valve replacement (TAVR) platform.
Zacks Industry Outlook Highlights: Teleflex, Medtronic, Johnson & Johnson, Hologic and Wright Medical
by Zacks Equity Research
Zacks Industry Outlook Highlights: Teleflex, Medtronic, Johnson & Johnson, Hologic and Wright Medical
Medtronic (MDT) Partners with Aetna for Type 1 & 2 Diabetes (Revised)
by Zacks Equity Research
Medtronic plc (MDT) inked a new outcomes-based collaboration with Aetna (AET) for type 1 and type 2 diabetes patients who are on doses of multiple daily insulin injections.
Medtronic (MDT) Partners with Aetna for Type 1 & 2 Diabetes
by Zacks Equity Research
Medtronic plc (MDT) recently inked a new 'outcomes-based' collaboration with Aetna (AET) for type 1 and type 2 diabetes patients who are on doses of multiple daily insulin injections.
Medtronic (MDT) Up 4.2% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Medtronic (MDT) A Suitable Value Pick Right Now?
by Zacks Equity Research
Let's find out if Medtronic PLC (MDT) stock is a good choice for value-oriented investors right now
Medtronic CRT Devices Improve Therapy Delivery, Cut Costs
by Zacks Equity Research
Medtronic plc (MDT) recently announced positive data on cardiac resynchronization therapy (CRT) devices within its Cardiac and Vascular segment.